Titlebook: Bortezomib in the Treatment of Multiple Myeloma; Irene M. Ghobrial,Paul G. Richardson,Kenneth C. An Book 2011 Springer Basel AG 2011 Borte

ARIA

,Bortezomib in Waldenstrom’s Macroglobulinemia,s. The enthusiastic preclinical and clinical results exerted by bortezomib in multiple myeloma, as well as other hematological malignancies including WM, has validated the idea that the proteasome is an important target in cancer therapy.

蕁麻

調(diào)味品

虛弱的神經(jīng)

Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics,ar protein complexes that degrade polyubiquitinated proteins. Bortezomib (Velcade.) is a boronic acid dipeptide that directly binds to enzymatic complex to block chimotrypsin-like activity of proteasome and is the first FDA-approved proteasome inhibitor for multiple myeloma (MM) treatment. Bortezomi

negligence

A保存的

奇思怪想